Zacks Investment Research on MSN
Corvus Pharmaceuticals stock rallies 209% in a month: Here's why
Shares of Corvus Pharmaceuticals CRVS have skyrocketed 208.8% in a month. The massive stock price rally was observed after ...
In January 2026, Corvus Pharmaceuticals reported past positive Phase 1 data from cohort 4 of its placebo-controlled trial of soquelitinib for moderate to severe atopic dermatitis, and moved ahead with ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results